Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...

The Tectonic management team will host one-on-one meetings during the two conferences. Interested investors should contact their Piper Sandler and Evercore representatives to schedule meetings.

As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...

The main market opportunities for CCR8-targeted immunotherapies lie in its potential to address unmet needs in cancer treatment by selectively depleting immunosuppressive Tregs in tumors, enhancing ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

The $1.3m grant from the Gates Foundation will allow Keltic Pharma Therapeutics to accelerate its ground-breaking malaria drug discovery programme, which is based on work from the laboratories of ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a ...

Septerna's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding. Read why SEPN stock ...

In this video, Omar Nadeem, MD, an assistant professor of medicine at Harvard Medical School, discusses the factors that impact if or when a patient with multiple myeloma will relapse.

Pandurangan Vijayanand , M.D., Ph.D., William K. Bowes Distinguished Professor at La Jolla Institute for Immunology ( LJI ), has even shown that a greater density of T RM cells is linked to better ...

There are many kinds of T cells, and they play different parts in defending the body. Some T cells kill infected cells, ...